WO2006029411A3 - Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof - Google Patents

Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof Download PDF

Info

Publication number
WO2006029411A3
WO2006029411A3 PCT/US2005/032553 US2005032553W WO2006029411A3 WO 2006029411 A3 WO2006029411 A3 WO 2006029411A3 US 2005032553 W US2005032553 W US 2005032553W WO 2006029411 A3 WO2006029411 A3 WO 2006029411A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
processes
mixtures
daltons
molecular weight
Prior art date
Application number
PCT/US2005/032553
Other languages
French (fr)
Other versions
WO2006029411A2 (en
Inventor
Irit Pinchasi
Ben-Zion Dolitzky
Anton Frenkel
Michal Schwartz
Ruth Arnon
Rina Aharoni
Original Assignee
Teva Pharma
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Yeda Res & Dev filed Critical Teva Pharma
Priority to DK05795337.4T priority Critical patent/DK1797109T3/en
Priority to ES05795337.4T priority patent/ES2572811T3/en
Priority to EP05795337.4A priority patent/EP1797109B1/en
Priority to SI200532068A priority patent/SI1797109T1/en
Publication of WO2006029411A2 publication Critical patent/WO2006029411A2/en
Publication of WO2006029411A3 publication Critical patent/WO2006029411A3/en
Priority to IL181802A priority patent/IL181802A/en
Priority to HRP20160455TT priority patent/HRP20160455T1/en
Priority to CY20161100457T priority patent/CY1117704T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Abstract

The invention provides a composition comprising a mixture of polypeptides, wherein each polypeptide (a) is a copolymer of the amino acids L-glutamic acid, L-alanine, L-tyrosine, and L-lysine, and (b) may be in the form of a pharmaceutically acceptable salt; and wherein in the mixture (i) the polypeptides have an average molecular weight in the range 13,500 to 18,500 daltons, (ii) 13% to 38% of the polypeptides have a diethylamide group instead of a carboxyl group present at one end thereof, and (iii) 68% of the polypeptides have a molecular weight between 7,000 and 41,000 daltons. In an embodiment, the average molecular weight is 16,000 daltons, and processes for preparing and its uses.
PCT/US2005/032553 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof WO2006029411A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DK05795337.4T DK1797109T3 (en) 2004-09-09 2005-09-09 MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
ES05795337.4T ES2572811T3 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing them and methods for obtaining them, and uses thereof
EP05795337.4A EP1797109B1 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
SI200532068A SI1797109T1 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
IL181802A IL181802A (en) 2004-09-09 2007-03-08 Compositions comprising mixtures of polypeptides, process for preparing same and uses thereof
HRP20160455TT HRP20160455T1 (en) 2004-09-09 2016-04-28 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
CY20161100457T CY1117704T1 (en) 2004-09-09 2016-05-24 POLYPeptide Mixtures, Compositions Containing and Procedures for their Preparation and Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60884404P 2004-09-09 2004-09-09
US60/608,844 2004-09-09

Publications (2)

Publication Number Publication Date
WO2006029411A2 WO2006029411A2 (en) 2006-03-16
WO2006029411A3 true WO2006029411A3 (en) 2006-08-03

Family

ID=36037053

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/032553 WO2006029411A2 (en) 2004-09-09 2005-09-09 Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof

Country Status (11)

Country Link
US (2) US7560100B2 (en)
EP (1) EP1797109B1 (en)
CY (1) CY1117704T1 (en)
DK (1) DK1797109T3 (en)
ES (1) ES2572811T3 (en)
HR (1) HRP20160455T1 (en)
HU (1) HUE028833T2 (en)
IL (1) IL181802A (en)
PL (1) PL1797109T3 (en)
SI (1) SI1797109T1 (en)
WO (1) WO2006029411A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CN1308683C (en) * 2001-12-04 2007-04-04 特瓦制药工业有限公司 Process for the measurement of the potency of glatiramer acetate
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP1592384B1 (en) * 2003-01-21 2012-10-31 Yeda Research And Development Co., Ltd. Cop 1 for treatment of inflammatory bowel diseases
CA2541445A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
KR101347105B1 (en) * 2004-06-25 2014-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. Compositions and methods for prophylaxis of neurological disorders
EP1799703B1 (en) * 2004-09-09 2010-01-06 Teva Pharmaceutical Industries Ltd Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
AU2006211510B8 (en) * 2005-02-02 2011-04-21 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
RS52867B (en) * 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (en) * 2005-04-25 2006-11-02 Yeda Research And Development Company Markers associated with the therapeutic efficacy of glatiramer acetate
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20090038701A1 (en) 2006-01-17 2009-02-12 Baxter International Inc. Device, system and method for mixing
WO2007084919A1 (en) * 2006-01-17 2007-07-26 Baxter International Inc. Device, system and method for mixing
CA2650653C (en) * 2006-04-28 2016-03-29 Momenta Pharmaceuticals, Inc. Methods of evaluating glatiramer acetate
ITMI20061274A1 (en) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche LIPID NANOPARTICELLAR VECTORS CONTAINING RELIEF AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CA2705046C (en) 2007-07-31 2015-03-03 Natco Pharma Limited Process for the preparation glatiramer acetate (copolymer-1)
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
EP2044951A1 (en) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
AU2008330093A1 (en) * 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
JP4647706B2 (en) * 2007-12-14 2011-03-09 江崎グリコ株式会社 α-Lipoic acid nanoparticles and preparation method thereof
EP2277050B2 (en) 2008-04-16 2022-09-28 Momenta Pharmaceuticals, Inc. Analysis of amino acid copolymer compositions
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
HUE046050T2 (en) * 2008-05-21 2020-01-28 Ferring Bv Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia
PL2307448T3 (en) * 2008-08-07 2015-10-30 Sigma Aldrich Co Llc Preparation of low molecular weight polylysine and polyornithine in high yield
BRPI0918718A2 (en) * 2008-08-07 2015-12-01 Scinopharm Taiwan Ltd glatiramer acetate synthesis
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
MX2011012315A (en) 2009-05-19 2011-12-16 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors.
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20110060279A1 (en) * 2009-07-15 2011-03-10 Ayelet Altman Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
ME02414B (en) * 2009-07-30 2016-09-20 Teva Pharma Treatment of crohn's disease with laquinimod
ES2586843T3 (en) * 2009-08-10 2016-10-19 Teva Pharmaceutical Industries Ltd. Treatment of disorders related to BDNF using laquinimod
ES2758554T3 (en) 2009-12-08 2020-05-05 Univ Case Western Reserve Range amino acids for treatment of eye disorders
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8641661B2 (en) * 2010-01-05 2014-02-04 Baxter International Inc. Mixing system, kit and mixer adapter
CA2726566A1 (en) * 2010-01-11 2011-07-11 Baxter International Inc. Pipette system, pipette tip assembly and kit
BR112012022187A2 (en) * 2010-03-03 2015-09-22 Teva Pharma rheumatoid arthritis treatment with the combination of laquinimod and methotrexate
WO2011109526A1 (en) * 2010-03-03 2011-09-09 Teva Pharmaceutical Industries Ltd. Treatment of lupus nephritis using laquinimod
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
RU2013108828A (en) * 2010-07-29 2014-09-10 Др. Редди'С Лабораторис Лтд. MARKERS OF MOLECULAR MASS OF GLATIAMETER ACETATE
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2627669B1 (en) 2010-10-11 2016-08-17 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
ES2660772T3 (en) 2010-11-15 2018-03-26 Neuroderm Ltd Continuous administration of L-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions therefor
WO2012067974A1 (en) * 2010-11-17 2012-05-24 Sigma-Aldrich Co. Llc. A greener method for the production of copolymer 1
PE20140872A1 (en) * 2010-12-07 2014-08-09 Teva Pharma USE OF LAQUINIMOD TO REDUCE FATIGUE, IMPROVE FUNCTIONAL STATUS AND IMPROVE QUALITY OF LIFE IN PATIENTS WITH MULTIPLE SCLEROSIS
EP2675893B1 (en) * 2011-02-18 2019-01-09 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
EP2688911B1 (en) 2011-03-24 2017-08-02 OPKO Pharmaceuticals, LLC Biomarker discovery in complex biological fluid using bead or particle based libraries
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
WO2013009864A1 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Structure assessment of heterogeneous polypeptide mixtures
WO2013009885A2 (en) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation of copolymer diethylamide
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
KR20140101333A (en) 2011-10-12 2014-08-19 테바 파마슈티컬 인더스트리즈 리미티드 Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CA2854431A1 (en) * 2011-11-03 2013-05-10 Biocon Limited Process for the preparation of random polypeptides and employing circular dichroism as a guidance tool for the manufacture of glatiramer acetate
EP2798351A4 (en) * 2011-12-12 2015-11-11 Biocon Ltd Development of specific immunoassay critical reagents for pharmacokinetic assessments of peptide polymers in preclinical and clinical matrices
AR089862A1 (en) 2012-02-03 2014-09-24 Teva Pharma USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH CROHN'S DISEASE IN THOSE WHO FAILS AN ANTI-FACTOR THUMOR NECROSIS THERAPY a (ANTI-TNFa) FIRST LINE
AR090885A1 (en) * 2012-05-02 2014-12-10 Teva Pharma USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
PL2854764T3 (en) 2012-06-05 2019-07-31 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
TW201400117A (en) 2012-06-05 2014-01-01 Teva Pharma Treatment of ocular inflammatory disease using laquinimod
TW201410244A (en) 2012-08-13 2014-03-16 Teva Pharma Laquinimod for treatment of GABA mediated disorders
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CN105377308B (en) 2013-03-14 2019-07-26 迈兰公司 Acetic acid copaxone responds biomarker mRNA efficacy determinations
UY35790A (en) 2013-10-21 2015-05-29 Teva Pharma GENETIC MARKERS THAT PREACH THE RESPONSE TO THE GLATIRAMER ACETATE
CN105917001B (en) * 2013-10-24 2020-11-20 迈兰公司 Human T cell line assay for assessing immunological identity of glatiramer acetate preparations
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
PT3116475T (en) 2014-03-13 2020-12-15 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
WO2015195605A1 (en) * 2014-06-17 2015-12-23 Teva Pharmaceutical Industries Ltd. Transmucosal delivery of glatiramer acetate by oral patches
CN105218646B (en) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 A kind of UPLC methods for detecting acetic acid copaxone sample
CN104844697B (en) * 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 The preparation method of acetic acid copaxone
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016176649A1 (en) * 2015-04-30 2016-11-03 Teva Pharmaceutical Industries Ltd. Method of determining the molecular weight distribution of glatiramer acetate using multi-angle laser light scattering (malls)
CA3016917A1 (en) 2016-04-27 2017-11-02 Immunomedics, Inc. Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
CN107550853B (en) * 2016-06-30 2020-06-12 深圳翰宇药业股份有限公司 Preparation method of glatiramer acetate injection
PT3436054T (en) 2016-09-13 2019-11-19 Allergan Inc Stabilized non-protein clostridial toxin compositions
CN110382052A (en) 2017-03-26 2019-10-25 Mapi医药公司 The copaxone store system of multiple sclerosis for therapeutic advance type form
CA3050332A1 (en) 2017-03-27 2018-10-04 Immunomedics, Inc. Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
CN110352201A (en) 2017-04-03 2019-10-18 免疫医疗公司 The subcutaneous administration of antibody drug conjugate for cancer therapy
US20190202984A1 (en) * 2018-01-03 2019-07-04 Kinbio Ltd. Process of preparing glatiramer acetate
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11497765B1 (en) 2022-02-27 2022-11-15 King Abdulaziz University Thioctamer expedites wound healing

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846550A (en) * 1971-01-21 1974-11-05 H Akrongold Cosmetic skin powder containing urea
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
JPS6053535A (en) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd Production of regular polyaminoacid resin
SU1182051A1 (en) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Polytripeptides possessing oenantic selectivity in reactions of hydrolysis of carbobenzoxy-d-1 alanine n-nitrophenyl esters
EP0228448B1 (en) 1985-06-18 1991-08-28 Emory University Use of biologically active copolymers for the manufacture of a medicament for stimulating the growth of an animal
DD257174A3 (en) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno PROCESS FOR PREPARING THE PEPTIDES Z ALA ALA LON P NITRANILIDE OR Z ASP ASP PHE OME WITH METALOPROTEASE
SU1469826A1 (en) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Copolymer of l-lysine and l-glutamic acid containing side groups and showing prolonged hypotensive activity and compensatory effect at hemorrhagic shock, and a method of its preparing
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
SU1690368A1 (en) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Statistic copolymers as low toxic compounds having prolonged hypotensive action and method for their production
DE3930733A1 (en) 1989-09-14 1991-03-28 Roehm Gmbh METHOD FOR PRODUCING A COMPLEX MEDICINAL PRODUCT
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US5639726A (en) * 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
CA2336238A1 (en) * 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (en) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Treatment of Crohn's disease with copolymer 1 and polypeptides
IL141021A0 (en) * 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
DE09004306T1 (en) 1998-09-25 2010-12-09 Yeda Research & Development Co., Ltd., Weizmann Institute of Science Copolymer 1-related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en) * 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2355400A1 (en) 1998-11-12 2000-05-18 Yeda Research And Development Co., Ltd. Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating gvhd and hvgd
EP1248643B1 (en) 2000-01-20 2005-08-17 YEDA RESEARCH AND DEVELOPMENT Co. LTD. The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy
AU2001238469C1 (en) 2000-02-18 2006-08-24 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
IL153236A0 (en) 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
CN1308683C (en) 2001-12-04 2007-04-04 特瓦制药工业有限公司 Process for the measurement of the potency of glatiramer acetate
US7309334B2 (en) * 2002-07-23 2007-12-18 Von Hoffmann Gerard Intracranial aspiration catheter
AU2003283152A1 (en) * 2002-11-13 2004-06-03 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
EP1592384B1 (en) * 2003-01-21 2012-10-31 Yeda Research And Development Co., Ltd. Cop 1 for treatment of inflammatory bowel diseases
CA2518079A1 (en) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
EP1638589B1 (en) * 2003-05-14 2014-03-26 Teva Pharmaceutical Industries Limited Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
CA2541445A1 (en) * 2003-10-31 2005-05-12 Teva Pharmaceutical Industries Ltd. Nanoparticles for drug delivery
WO2005048435A1 (en) * 2003-11-13 2005-05-26 Sew-Eurodrive Gmbh & Co. Kg Compact drive
WO2005084377A2 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
EP1799703B1 (en) * 2004-09-09 2010-01-06 Teva Pharmaceutical Industries Ltd Process for preparation of mixtures of polypeptides using purified hydrobromic acid
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
ES2331015T3 (en) 2004-10-29 2009-12-18 Sandoz Ag PROCESS FOR THE PREPARATION OF A GLATIRAMERO.
AU2006211510B8 (en) * 2005-02-02 2011-04-21 Teva Pharmaceutical Industries, Ltd. Process for producing polypeptide mixtures using hydrogenolysis
WO2007030573A2 (en) * 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
US20070161566A1 (en) * 2006-01-11 2007-07-12 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
ES2338488T3 (en) 2006-07-05 2010-05-07 Momenta Pharmaceuticals, Inc. IMPROVED PROCESS FOR THE PREPARATION OF COPOLIMERO-1.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AHARONI R.: "Copolymer 1 inhibits manifestations of graft rejection", TRANSPLANTATION, vol. 72, no. 4, August 2001 (2001-08-01), pages 598 - 605, XP009042375 *
TEILTELBAUM D.: "Copolymer 1 induces T cells for the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis", PROC. NATL. ACAD. SCI. USA, vol. 94, no. 20, September 1997 (1997-09-01), pages 10821 - 10826, XP002918836 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9155776B2 (en) 2009-08-20 2015-10-13 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9402874B2 (en) 2009-08-20 2016-08-02 Yeda Research & Development Co., Ltd. Low frequency glatiramer acetate therapy
US9499868B2 (en) 2011-10-10 2016-11-22 Teva Pharmaceutical Industries, Ltd. Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate

Also Published As

Publication number Publication date
HRP20160455T1 (en) 2016-07-15
SI1797109T1 (en) 2016-07-29
PL1797109T3 (en) 2016-11-30
EP1797109B1 (en) 2016-02-24
IL181802A0 (en) 2007-07-04
US20060122113A1 (en) 2006-06-08
ES2572811T3 (en) 2016-06-02
IL181802A (en) 2016-10-31
HUE028833T2 (en) 2017-01-30
US20070054857A1 (en) 2007-03-08
EP1797109A2 (en) 2007-06-20
WO2006029411A2 (en) 2006-03-16
CY1117704T1 (en) 2017-05-17
EP1797109A4 (en) 2009-06-17
DK1797109T3 (en) 2016-04-11
US7560100B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
WO2006029411A3 (en) Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
WO2007030573A3 (en) Polypeptides useful for molecular weight determinations
DE60204714D1 (en) PHARMACOLOGICAL FOOD COMPOSITION FOR FOOD SUPPLEMENT AND NUTRITIONAL IMPROVEMENT
WO2010051541A3 (en) Compositions containing delta-9-thc-amino acid esters and process of preparation
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
CA2339290A1 (en) Reaction products of hyaluronic acid and natural amino acids and their use in cosmetic and pharmaceutical compositions
CA2380569A1 (en) Chimeric polypeptides, method for production and uses thereof
CA2411786A1 (en) A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
WO2008101017A3 (en) Glucagon/glp-1 receptor co-agonists
WO2007097903A3 (en) Hiv fusion inhibitor peptides with improved biological properties
EP2311871A3 (en) IL-1 antagonist stable liquid formulation
WO2005023866A3 (en) Peptides that inhibit complement activation
PL334365A1 (en) Stable liquid inteferon formulations
EP2676673A3 (en) Glucagon/glp-1 receptor co-agonists
CA2563185A1 (en) Sustained release formulations of a peptide or protein and a purified gallic acid ester
CA2370289A1 (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
CA2203033A1 (en) Compounds and compositions for delivering active agents
GEP20084298B (en) Amino acids with affinity for the alpha−2−delta−protein
WO2005115174A3 (en) Alpha-msh-antagonist didpeptide conjugates
CA2242646A1 (en) Amino acid composition
WO1999060013A3 (en) Il-6 antagonist peptides
AU2003283152A1 (en) Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
AU2003286404A1 (en) Peptide nanostructures, methods for their preparation and use
CA2467708A1 (en) Resin composition and method for producing the same
AU2001284419A1 (en) Novel polypeptides and anti-hiv drugs containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 181802

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005795337

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005795337

Country of ref document: EP